Drug intelligence / Profile preview

Alin Depot (dexamethasone isonicotinate)

Development stage
Approved
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Intraarticular, Intradermal, Intramuscular
01

Overview

Alin Depot is a sustained-release injectable formulation of dexamethasone isonicotinate, a synthetic glucocorticoid corticosteroid. Developed by Chinoin, it is designed to provide prolonged anti-inflammatory and immunosuppressive effects. The formulation utilizes microcrystalline technology to allow slow, continuous, and regulated release of the active drug into the systemic circulation over a period of up to 14 days following a single intramuscular injection. Dexamethasone isonicotinate acts as an agonist of the glucocorticoid receptor, modulating gene expression to suppress pro-inflammatory cytokines and enhance anti-inflammatory mediators. It is approved for the treatment of various acute and chronic inflammatory, allergic, and rheumatic conditions, including rheumatoid arthritis, asthma, eczema, and dermatitis, in both human and veterinary medicine.

Brand names
Alin DepotAuxilosonAuxilsonAuxilsoneVoren
Other names
dexamethasone 21-(4-pyridinecarboxylate)dexamethasone 21-isonicotinatedexamethasone21-isonicotinatedexamethasone-21-isonicotinateisonicotinic acid dexamethasone-21 ester
02

Targets

GR (Glucocorticoid receptor)PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)NCOA1 (Nuclear receptor coactivator 1)

Beyond the preview

Go deeper on Alin Depot (dexamethasone isonicotinate).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alin Depot (dexamethasone isonicotinate).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call